The porcine vaccines market has witnessed significant growth in the past few years owing to growing demand for pork meat worldwide. Porcine vaccines are formulated to prevent infectious diseases in swine animals and ensure livestock health. They protect pigs against various viral and bacterial infections like classical swine fever, foot-and-mouth disease, porcine circovirus, mycoplasma, and Escherichia coli. These vaccines help maintain a disease-free environment for pigs.
The global porcine vaccines market is estimated to be valued at US$ 2.4 Bn in 2023 and is expected to exhibit a CAGR of 5.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The growing demand for pork meat worldwide has accelerated the growth of the porcine vaccines market. As per statistics, pig meat accounted for over 40% of the total meat consumption globally in 2020. This robust demand has encouraged pig farmers to adopt prophylactic vaccination practices for disease prevention and continuous supply of healthy pork. Moreover, many developing countries are increasingly investing in commercial pig farming to meet the rising demand for pork. The growing commercial pig farming activities necessitate the use of porcine vaccines for disease management. Furthermore, various governments are also taking initiatives to curb the spread of transboundary pig diseases by promoting vaccinations programs among farmers. These factors are contributing significantly to the growth of the porcine vaccines market over the forecast period.
Segment Analysis
The global porcine vaccines market is segmented on the basis of technology, disease indication and geography. Under technology, the live attenuated vaccines segment accounts for a dominant share owing to high efficacy. Live attenuated vaccines induce appropriate immunological responses that provides adequate protection against the targeted disease.
Key Takeaways
The global porcine vaccines market is expected to witness high growth. The global porcine vaccines market is estimated to be valued at US$ 2.4 Bn in 2023 and is expected to exhibit a CAGR of 5.2% over the forecast period 2023 to 2030.
Regional analysis related content comprises
The Asia Pacific region dominates the global porcine vaccines market with over 45% share. Rapid expansion of pig farming in China, Vietnam and other southeast Asian countries to meet the rising pork demand fuels the market growth. Additionally, frequent outbreak of swine diseases and government support for disease control programs propels the adoption of vaccinations.
Key players related content comprises
Key players operating in the porcine vaccines market are Boehr, Merck, Zoetis, Hipra, CE-VA, and Ringpu Biology. Boehr leads the market for porcine vaccines in China with wide portfolio addressing major diseases like PRRS, CSF and FMD. Merck and Zoetis together hold over 30% market share globally with strong pipeline and commercialization capabilities.
No comments:
Post a Comment